Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07167134
PHASE3

Evolution of Hypofractionated Stereotactic Irradiation for Radio-Resistant Brain Metastases From D1-3-5 to D1-2-3

Sponsor: Centre Paul Strauss

View on ClinicalTrials.gov

Summary

The goal of this prospective, multi-center, randomized double-arm clinical trial is to demonstrate a benefit in term of local control of a shorter spread of hypofractionated stereotactic radiotherapy at D1-2-3 vs D1-3-5, in the treatment of "radioresistant" Brain Metastases (BM). This trial aims to recruit patients with 1 to 5 unoperated BM originating from radioresistant primary sites. Patients will be randomly assigned to either the D1-3-5 radiotherapy arm or the D1-2-3 radiotherapy arm. Stereotactic brain irradiation will be administered at a dose of 33 Gy delivered in 3 fractions.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

264

Start Date

2025-10

Completion Date

2030-04

Last Updated

2025-09-11

Healthy Volunteers

No

Interventions

RADIATION

D1-3-5 radiotherapy

23.1 Gray (Gy) delivered in 3 fractions of 7.7 Gy at D1, D3, and D5

RADIATION

D1-2-3 radiotherapy

23.1 Gray (Gy) delivered in 3 fractions of 7.7 Gy at D1, D2, and D3

Locations (1)

ICANS

Strasbourg, France